
-
Krystal Biotech NasdaqGS:KRYS Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Location: 2100 Wharton Street, Pittsburgh, PA, 15203, United States | Website: https://www.krystalbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.023B
Cash
616.8M
Avg Qtr Burn
N/A
Short % of Float
11.40%
Insider Ownership
12.21%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VYJUVEKTM (B-VEC) (Topical Beremagene Geperpavec) Details Skin disease/disorder, Dystrophic epidermolysis bullosa, Epidermolysis bullosa | Approved Quarterly sales | |
KB803 (Ophthalmic B-VEC) Details Dystrophic epidermolysis bullosa | Phase 3 Initiation | |
KB301 Details Wrinkles | Phase 2 Initiation | |
KB105 Details Skin disease/disorder, TGM1-deficient lamellar ichthyosis | Phase 1/2 Initiation | |
KB707 (IL-2 and IL-12) Details Solid tumor/s, Multiple tumors, Cancer | Phase 1 Data readout | |
KB304 Details Wrinkles | Phase 1 Data readout | |
KB408 Details Severe alpha-1 antitrypsin deficiency | Phase 1 Data readout | |
KB407 Details Cystic fibrosis | Phase 1 Data readout | |
Inhaled KB707 Details Solid tumor/s, Lung Metastases, Cancer | Phase 1 Data readout |